Kindred Biosciences Announces Completion of Mirataz® (mirtazapine transdermal ointment) Transaction

San Francisco, California (April 15, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has completed the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million, and royalties on worldwide sales. “We are pleased […]

Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs

San Francisco, California (March 24, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field efficacy study of KIND-025, a canine fusion protein targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of atopic dermatitis in dogs. The […]

Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results

San Francisco, California (March 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million and royalties on worldwide […]

Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, March 16, 2020. San Francisco, California (March 3, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its fourth quarter and year-end 2019 financial results […]

Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit

San Francisco, California (February 18, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch Animal Health Summit on February 24 in New York City. Dr. Richard Chin, Chief Executive Officer, will present and be available for one-on-one […]